Search

Your search keyword '"LADENSTEIN, Ruth"' showing total 575 results

Search Constraints

Start Over You searched for: Author "LADENSTEIN, Ruth" Remove constraint Author: "LADENSTEIN, Ruth" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
575 results on '"LADENSTEIN, Ruth"'

Search Results

1. A human neural crest model reveals the developmental impact of neuroblastoma-associated chromosomal aberrations

2. Comparative transcriptomics coupled to developmental grading via transgenic zebrafish reporter strains identifies conserved features in neutrophil maturation

3. Barriers and facilitators to implementation of the interoperable Survivorship Passport (SurPass) v2.0 in 6 European countries: a PanCareSurPass online survey study

4. Solid Tumours

6. International benchmarking of stage at diagnosis for six childhood solid tumours (the BENCHISTA project): a population-based, retrospective cohort study

7. Maintenance therapy with trofosfamide, idarubicin and etoposide in patients with rhabdomyosarcoma and other high-risk soft tissue sarcomas (CWS-2007-HR): a multicentre, open-label, randomised controlled phase 3 trial

9. Retrospective comparative analysis of two medical evacuation systems for Ukrainian patients affected by war

10. Barriers and facilitators to the implementation of a new European eHealth solution (SurPass v2.0): the PanCareSurPass Open Space study

12. Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial

13. Twinning to reduce research and innovation inequalities in paediatric solid tumours across Europe

14. Scaling up and implementing the digital Survivorship Passport tool in routine clinical care – The European multidisciplinary PanCareSurPass project

16. Single-cell transcriptomics and epigenomics unravel the role of monocytes in neuroblastoma bone marrow metastasis

18. Correction: Barriers and facilitators to the implementation of a new European eHealth solution (SurPass v2.0): the PanCareSurPass Open Space study

19. High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008.

20. Risk stratification in neuroblastoma patients through machine learning in the multicenter PRIMAGE cohort.

21. Long-Term Outcomes and Quality of Life of High-Risk Neuroblastoma Patients Treated with a Multimodal Treatment Including Anti-GD2 Immunotherapy: A Retrospective Cohort Study.

22. Primary Mediastinal Ewing's Sarcoma: Post Hoc Analysis from Two International Multicenter Prospective Randomized Trials.

23. Early Impact of Severe Acute Respiratory Syndrome Coronavirus 2 on Pediatric Clinical Research: A Pan-European and Canadian Snapshot in Time

24. Factors Influencing Implementation of the Survivorship Passport: The IT Perspective

25. Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup

27. Reproducibility Analysis of Radiomic Features from T2-weighted MRI after Processing and Segmentation Alternations in Neuroblastoma Tumors

28. Radiotherapy and long-term sequelae in pediatric patients with parameningeal rhabdomyosarcoma : Results of two Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registry

29. IT-Related Barriers and Facilitators to the Implementation of a New European eHealth Solution, the Digital Survivorship Passport (SurPass Version 2.0): Semistructured Digital Survey

30. Common core variables for childhood cancer data integration

31. Barriers and facilitators to implementation of the interoperable Survivorship Passport (SurPass) v2.0 in 6 European countries: a PanCareSurPass online survey study

32. Solid Tumours

33. Use Cases Requiring Privacy-Preserving Record Linkage in Paediatric Oncology.

34. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

35. The PanCareSurFup consortium: research and guidelines to improve lives for survivors of childhood cancer

36. The ‘Survivorship Passport’ for childhood cancer survivors

37. Supplementary Figure S2 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial

38. Supplementary Data S2 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial

39. Supplementary Table S5 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial

40. Study Protocol S1 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial

41. Development of a centralised triage centre for children with cancer and blood disorders in response to the humanitarian crisis in Ukraine

42. Zoledronic acid add-on therapy for standard-risk Ewing sarcoma patients in the Ewing 2008R1 trial

43. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial

44. PRIMAGE project: predictive in silico multiscale analytics to support childhood cancer personalised evaluation empowered by imaging biomarkers

45. Childhood Cancer Survivorship Passport Challenges in the European Health Data Space.

46. Assessment of HL7 FHIR Interoperability Between EHR Systems and the Survivorship Passport v2.0 Platform to Generate Treatment Summaries for Childhood Cancer Survivors in Six Clinics: Preliminary Testing Results.

47. Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial.

48. Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study

49. Multimodal Therapy with Consolidating Haploidentical Stem Cell Transplantation and Dinutuximab Beta for Patients with High-Risk Neuroblastoma and Central Nervous System Relapse

50. Which Patients With Rhabdomyosarcoma Need Radiotherapy? Analysis of the Radiotherapy Strategies of the CWS-96 and CWS-2002P Studies and SoTiSaR Registry

Catalog

Books, media, physical & digital resources